362 Index Name Paper ref. Name Paper ref. Rahimian, R Wed 254 Rahimi-Moghaddam, P Tue 105, Tue 485 Rahmoun, I Mon 290 Rai, J FC01.2.6 Raimundo, J Tue 162 Rain, M Mon 136 Raine, JM FC04.3.1 Rainio, E Tue 429 Raisman, R Mon 469 Raj, VL YI.04, Tue 254 Rajabi, O Tue 052 Rajabnia, M Mon 230 Rajaian, H Tue 015 Rajakannan, T FC04.3.7 Rajbanshi, S Mon 091 Rakhshandehroo, M Thu 438 Ralevic, V Wed 023 Ram, Birendra Mon 028 Ram, M Mon 028 Rama, AC Mon 376 Ramachandran, V Thu 380 Ramadaniati, H Thu 011 Ramajo, M Thu 264, Thu 240, Wed 215, Mon 206, Tue 144 Ramanujan, S Tue 196 Ramaswamy, M Mon 070 Ramenckaya, G Tue 129 Ramenskaya, GV Thu 253, Ramer, R Thu 337 Ramirez, E Mon 451 Ramírez, O Mon 023, W04.1.3 Ramírez-Rosas, MB W13.3 Ramsjö, M Tue 489, Tue 308 Randhawa, MA Thu 338 Rane, A Thu 256, Tue 318, Tue 138, FC14.1.6, Wed 183, Wed 176 Rangachari, PK W20.3, Tue 368 Rankin, L Wed 132 Rantakari, P Mon 215 Ranta-Panula, V Thu 052, Thu 071 Rao, A FC12.5.4 Rao, PGM FC04.3.7 Rao, V Wed 318, Wed 319 Raskovic, A Tue 454, Rasmussen, M Mon 450 Rasmussen, MH Mon 227 Rasmussen, MNP Thu 053 Rasouli, A Wed 301 Rassouli, A Tue 191 Rastinejad, F FC18.4.1 Rathbone, D Wed 057 Rathje, MA YI.10, Tue 053 Rattazzi, L Tue 256, Thu 434 Rauch, A W33.2 Raunsø, J FC04.2.4 Rautio, A Mon 076 Ravna, AW Mon 224 Ray, A FC16.4.2 Rayate, S Thu 333 Raynaud, F FC11.3.3 Rayyan, M Wed 001 Razik, F Wed 149 Rebola, N YI.10 Rebollo, A Tue 133 Rebsamen, M Tue 305 Rebsamen, MC Tue 166 Recinella, L Mon 105, Wed 329, Wed 434 Recio, MC Wed 300 Recio, P Mon 411 Rédei, D Thu 307 Redondo, S W09.3, Mon 206, Tue 144, Wed 228, Thu 240, Thu 264 Reed, DM Thu 241 Reed, G Wed 158 Rees, K FC03.3.6 Reeta, KH Mon 452, Reeves, J Mon 443 Refsum, H Tue 490, Wed 412 Regla, I Tue 420 Reglodi, D Mon 110, Mon 106, Mon 318 Reguillo, F Thu 240, Wed 215, Mon 206 Reichel, C Tue 227 Reiner, Z Mon 048 Reis, DG Wed 411 Reiter, RJ Mon 407 Rekik, M Tue 205, Tue 206, Tue 204 Rembold, CM W04.3.4 Remirez-Figueredo, D Wed 159, Thu 339 Ren, Junguo Thu 340 Ren, S Thu 390 Ren, X W02.1.6 Resende, AC Wed 341, Wed 340, Wed 342 Resstel, L Wed 411 Reul, J FC17.5.2 Reuther, L Wed 160, Wed 161 Reyes-Vega, JJ Thu 246 Reynolds, RF FC04.2.1 Rezania, F Thu 180 Rezapourian, P Thu 209 Rezayat, M Wed 437 Rezazadeh, H Mon 294 Rheeders, M Thu 016, Thu 012 Riba, P Thu 192 Ribeiro, CF YI.08, Thu 193 Ribeiro, RA Tue 255 Ribel-Madsen, R Mon 406 Ribuot, C Thu 245 Ricciotti, E Mon 281 Richards, B Wed 110 Richards, J FC14.3.5 Richards, S Tue 353 Richelsen, B FC05.1.1 Rickhag, M FC02.3.6 Rieder, M Wed 013 Rieder, MJ FC10.2.5 Riegel, C Mon 463 Riggi, C Wed 010 Righetti, L Thu 440 Rigoni, VLC Thu 351, Thu 352 Rimando, A Mon 443 Rimondini, R FC14.1.5 Rinken, A Tue 192, Thu 077 Rinne, P Thu 243 Ríos, JL Wed 300 Risso, A Tue 362 Ristic, S Wed 343 Ristimäki, A FC09.4.3 Riva, MA SS01.3
Name Paper ref. Name Paper ref. Rivera, L Wed 225, Wed 224 Rizzo, G FC18.4.5 Robays, H Mon 365, Tue 306 Roberts, RR Tue 322, Mon 064 Robertson, G W06.3 Robillard, K FC02.4.5, Mon 070 Robinson, E Wed 392, Thu 439 Robinson, K Thu 393 Robson, R Mon 259 Rocha, L Mon 095, Mon 097, Mon 094 Rocha, M Mon 383 Rocha-Pereira, C Thu 054 Roche, M Thu 021 Roda, JM Mon 079 Rodchenkov, GM Wed 175 Rodeiro-Guerra, I Wed 344 Rodell, A Tue 193 Roden, DM W23.3 Roden, M FC05.4.1 Rodrigo, M Tue 196 Rodrigo, T Wed 174 Rodrigues, E Thu 025 Rodrigues, ES Thu 061 Rodriguez, AB Mon 407, Wed 352 Rodriguez, B FC07.2.3 Rodríguez, C W09.4 Rodriguez, E Thu 240, Thu 399 Rodríguez, G Thu 358 Rodríguez, JC Mon 023, W04.1.3 Rodriguez, L Thu 358 Rodriguez, M Mon 229, Mon 080 Rodríguez, R Mon 023, W04.1.3 Rodríguez-Franco, MI Mon 079 Rodriguez- Gaztelumendi, A Thu 408 Rodriguez-Mañas, L Tue 134 Rodriguez-Salazar, M Tue 150 Rodríguez-Soriano, NY Tue 150 Rogava, MA Mon 192, Mon 216 Rogava, M Tue 174 Rogers, M Tue 284 Roglans, N Tue 133 Rognan, D Wed 216 Roh, H-K Tue 489 Roivainen, A Mon 256 Rojas, J Tue 362 Rolan, P Wed 113 Rollason Gumprecht, V Tue 305 Rollema, H FC14.2.3 Romacho, T Tue 134 Roman, A Mon 374 Roman-Campos, D FC03.1.5 Romano, Adele Thu 440 Romao, C Thu 202 Romashenko, O Tue 175 Rombouts, SARB Mon 400 Romero, E Thu 271 Romero-Gomez, M Tue 123 Romijn, JA Tue 148 Rommelfanger, K W01.2.4 Rompré, P-P FC17.4.6 Romualdi, P FC14.1.5 Rónai, A Thu 094 Rondard, P FC11.2.1 Rondinelli, S Wed 081 Rong, Z-X Thu 368 Rønn, JH Tue 161 Roohbakhsh, A Thu 412 Rosa, AC Thu 434 Rosa, AC Tue 256 Rosa, S Tue 257 Roschin, V Wed 347 Roscioni, SS Tue 242, Wed 095 Roseboom, P Thu 410 Rose'Meyer, R Tue 135 Rosén, I Thu 008 Rosenbaum, D S FC06.1.3 Rosenblad, M Wed 092 Rosenborg, S FC13.4.5 Rosenkilde, MM FC11.2.4, FC11.5.5 Röshammar, D Wed 136 Roskos, L Mon 228 Ross, G FC12.1.5 Ross, R Tue 284 Rossi, M Thu 062 Rossier, BC FC12.3.4 Rossier, MF Tue 166 Rossini, M Tue 362 Rosskopf, D Wed 119 Rossoni, L Wed 231, Wed 042 Rostami-Hodjegan, A FC07.2.1, FC10.3.5 Rothman, KJ FC04.1.3 Rouet, P Wed 196 Rouget, C Tue 205, Tue 206, Tue 204 Roughead, E FC13.1.6 Rouholamin, M Thu 391, Thu 392 Rouillard, C FC17.4.6, Wed 443 Rouleau, A Wed 051 Roulet, E Wed 108, Wed 102 Rousseau, A Wed 011 Roustit, M Wed 208, Thu 244, Thu 245 Roux, T Thu 035 Roviezzo, F Thu 081 Rovira, EE Thu 048 Rowan, M Mon 453 Rowland, I Wed 307 Rowlands, DK Tue 139, Thu 341 Royer, C FC18.3.5 Röyttä, M W21.4 Rozas, I Thu 399 Rozehnal, V Tue 039 Ruan, J Mon 077, Mon 078 Ruangnapa, T Mon 355 Ruangrut, P Wed 124 Rubets, I Tue 228, Wed 122 Rubie, P Tue 309 Rubino, A Tue 093 Rubio, V Mon 254 Rucman, R W02.3.1 Rudberg, I Tue 490 Rudd, JA Tue 471 Rueda, E Wed 250, Mon 278 Rueda, J Tue 165, Tue 163 Rüegg, UT W04.3.2, Wed 102, Wed 108, Thu 013 Ruengprasertkit, C Thu 357 Rui, Y-C Thu 210 Ruiz- Moreno, MI Thu 246 Index 363
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303:
FC15 Endothelium in health and dise
- Page 304 and 305:
FC16 Natural products: Past and fut
- Page 306 and 307:
FC16 Natural products: Past and fut
- Page 308 and 309:
FC16 Natural products: Past and fut
- Page 310 and 311:
FC16 Natural products: Past and fut
- Page 312 and 313:
FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor